(Total Views: 592)
Posted On: 04/27/2021 8:25:16 PM
Post# of 153988
“So you are posting speculation as fact since you don't know what the prior protocols were.”
No, it’s a fact that the first protocol was subtitled with two doses. If it wasn’t, why was the PR below released, stating that a new protocol with doses EXTENDED to 4?
“CytoDyn Files New Protocol with U.S. FDA for 4 Doses of Leronlimab for Critically Ill COVID-19 Patients..”
“announced today that after several weeks of discussions with the U.S. Food and Drug Administration (“FDA”) and analysis of CD12 trial data, and in particular the 82% survival results over placebo after two weeks of leronlimab treatment, with statistically significant p-value of 0.0233, the Company has filed a new protocol to extend treatment to four weeks .”
https://www.cytodyn.com/newsroom/press-releas...4-doses-of
No, it’s a fact that the first protocol was subtitled with two doses. If it wasn’t, why was the PR below released, stating that a new protocol with doses EXTENDED to 4?
“CytoDyn Files New Protocol with U.S. FDA for 4 Doses of Leronlimab for Critically Ill COVID-19 Patients..”
“announced today that after several weeks of discussions with the U.S. Food and Drug Administration (“FDA”) and analysis of CD12 trial data, and in particular the 82% survival results over placebo after two weeks of leronlimab treatment, with statistically significant p-value of 0.0233, the Company has filed a new protocol to extend treatment to four weeks .”
https://www.cytodyn.com/newsroom/press-releas...4-doses-of
(3)
(2)
